• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Research Brief on 4-(aminomethyl)-3-fluoroaniline (CAS: 900174-91-6) in Chemical Biology and Pharmaceutical Applications

4-(aminomethyl)-3-fluoroaniline (CAS: 900174-91-6) is a fluorinated aromatic amine derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapeutics. Recent studies have highlighted its role in modulating protein-protein interactions and enhancing drug-like properties of lead compounds.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 4-(aminomethyl)-3-fluoroaniline as a building block for novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this scaffold to develop compounds with improved selectivity profiles and pharmacokinetic properties. The fluorine substitution at the 3-position was found to significantly influence the binding affinity through favorable interactions with hydrophobic pockets in the target protein.

In the field of PET tracer development, 4-(aminomethyl)-3-fluoroaniline has shown promise as a precursor for radiolabeled probes. A recent Nature Communications article (2024) described its incorporation into fluorine-18 labeled tracers for imaging neuroinflammation. The compound's ability to cross the blood-brain barrier while maintaining metabolic stability makes it particularly valuable for CNS-targeted diagnostics.

The synthetic accessibility of 4-(aminomethyl)-3-fluoroaniline has been improved through recent methodological advances. A 2024 Organic Process Research & Development publication detailed a scalable, continuous-flow synthesis route that achieves >90% yield with excellent purity. This development addresses previous challenges in large-scale production and has facilitated broader investigation of its pharmaceutical applications.

Emerging research suggests potential applications of 4-(aminomethyl)-3-fluoroaniline in covalent drug design. The primary amine functionality allows for conjugation with various electrophiles, enabling the development of targeted covalent inhibitors. Recent computational studies have modeled its interactions with cysteine residues in target proteins, providing insights for rational drug design approaches.

Safety and toxicological evaluations of 4-(aminomethyl)-3-fluoroaniline have progressed significantly, with recent in vitro and in vivo studies demonstrating favorable profiles at therapeutic concentrations. However, researchers emphasize the need for careful handling due to potential aromatic amine reactivity. Current good manufacturing practice (cGMP) guidelines for its production and handling were updated in 2023 to reflect these safety considerations.

The compound's unique physicochemical properties, including its logP value of 1.2 and pKa of 4.7, make it particularly suitable for medicinal chemistry applications requiring balanced solubility and membrane permeability. Recent structure-activity relationship studies have correlated these properties with improved in vivo efficacy in several therapeutic areas.

Future research directions for 4-(aminomethyl)-3-fluoroaniline include exploration of its use in PROTAC (proteolysis targeting chimera) design and as a linker in antibody-drug conjugates. Preliminary results from ongoing studies suggest that its incorporation can enhance tissue specificity and reduce off-target effects in these advanced therapeutic modalities.

• 771571-82-5(Benzenemethanamine,5-amino-2-fluoro-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)